Asset profile
Hydromethylthionine mesylate
Small molecule
Evidence outlook · results not reported
NCT03446001 · Alzheimer Disease
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT03446001: This was a large randomized, quadruple-blind, placebo-controlled trial with 598 participants and clinical primary measures of cognition and activities of daily living. The 16-mg dose numerically favored treatment on both measures at 52 weeks, but the registry does not state whether either primary comparison was statistically significant, so the findings provide meaningful but inconclusive evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 6 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Hydromethylthionine Mesylate: this drug | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) | ||
| GV1001 | Phase 3 | Peptide | Telomerase (hTERT) | ||
| Lemborexant (Dayvigo) | Phase 3 | Small molecule | Orexin receptor (repositioned) | ||
| Masitinib | Phase 3 | Small molecule | c-Kit/Lyn/Fyn tyrosine kinases (mast cell/microglia), c-Kit (CD117); also PDGFR, Lck, FAK, FGFR3, CSF1R, KIT (c-Kit), also PDGFR and Lyn/Fyn kinases |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.